Taysha Gene Therapies, Inc.
TSHA
$4.06
-$0.37-8.35%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -36.36% | -37.09% | -48.97% | -46.07% | -30.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -36.36% | -37.09% | -48.97% | -46.07% | -30.90% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -36.36% | -37.09% | -48.97% | -46.07% | -30.90% |
| SG&A Expenses | 10.81% | 2.99% | -0.10% | -9.51% | -19.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.36% | 8.15% | -2.53% | 9.36% | 5.63% |
| Operating Income | -23.81% | -15.71% | -5.77% | -21.36% | -12.80% |
| Income Before Tax | -338.82% | 18.90% | 26.47% | 19.96% | 89.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -338.82% | 18.90% | 26.47% | 19.96% | 89.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -338.82% | 18.90% | 26.47% | 19.96% | 89.38% |
| EBIT | -23.81% | -15.71% | -5.77% | -21.36% | -12.80% |
| EBITDA | -24.39% | -16.23% | -6.08% | -21.96% | -13.13% |
| EPS Basic | -432.32% | 62.68% | 71.88% | 73.71% | 97.57% |
| Normalized Basic EPS | -1,558.26% | 66.61% | 75.24% | 76.65% | 99.04% |
| EPS Diluted | -432.32% | 62.68% | 71.88% | 73.71% | 97.57% |
| Normalized Diluted EPS | -1,558.26% | 66.61% | 75.24% | 76.65% | 99.04% |
| Average Basic Shares Outstanding | 26.15% | 37.87% | 64.35% | 115.67% | 204.43% |
| Average Diluted Shares Outstanding | 26.15% | 37.87% | 64.35% | 115.67% | 204.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |